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ABSTRACT  
Objective: To develop a simple, precise, accurate, method was developed and validated for analysis of metformin hydrochloride (MET) and 
empagliflozin in (EMPA) in bulk and tablet dosage form.  
Methods: The method used a reverse phase column, dikma C18 (50×2.1 mm, 1.8 μ), a mobile phase comprising of phosphate buffer (pH-3): 
methanol (30:70 v/v) flow rate of 1.0 ml/min and a detection wavelength of 240 nm using a photodiode array detector. The proposed method was 
validated for various parameters like linearity, precision, accuracy, robustness, ruggedness, detection, quantification limits, stability studies, 
formulation analysis as per International Conference on Harmonization (ICH) guidelines. 
Results: The retention time was found to be 1.189 min and 1.712 min for MET and EMPA respectively. The proposed method was found to be 
having linearity in the concentration range of 500-2500 μg/ml for MET (r2=0.989) and 5-25 μg/ml for EMPA (r2=0.994), respectively. The mean % 
recoveries obtained were found to be 100.35-100.48% for MET and 99.80-101.30% for EMPA respectively. Stress testing which covered acid, base, 
peroxide, photolytic and thermal degradation was performed on under test to prove the specificity of the method and the degradation was achieved. 
The developed method has been statistically validated according to International Conference on Harmonization (ICH) guidelines.  
Conclusion: Thus, the proposed method can be successfully applied for the stability indicating the simultaneous determination of MET and EMPA in 
bulk and combined tablet dosage form and in the routine quality control analysis.  
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Metformin (MET) hydrochloride is chemically named as (3-(diamino 
methylidene)-1, 1-dimethylguanidine hydrochloride. It has a 
molecular formula of C4H12ClN5 and the molecular weight is 165.62 
g/mol. MET is an oral anti-hyperglycemic agent (Type 2 diabetes) 
belongs to a class of biguanides and useful for treating non-insulin 
dependent diabetes mellitus. MET decreases blood glucose levels by 
decreasing hepatic glucose production, decreasing intestinal 
absorption of glucose, and improving insulin sensitivity by 
increasing peripheral glucose uptake and utilization. These effects 
are mediated by the initial activation by MET of AMP-activated 
protein kinase, a liver enzyme that plays an important role in insulin 
signaling, whole body energy balance, and the metabolism of glucose 
and fats [1-5]. 
Empagliflozin (EMPA) is chemically named as 1-chloro-4-[b-D-
glucopyranos-1-yl]-2-[4-([S]-tetrahydrofuran–3–yl-oxy) benzyl]-
benzene (fig. 2). It has a molecular formula of C23H27ClO7 and 
molecular weight is 450.912 g/mol. Empagliflozin is an orally 
administered selective sodium glucose cotransporter-2 (SGLT-2) 
inhibitor, which lowers blood glucose in people with type 2 diabetes 
by blocking the reabsorption of glucose in the kidneys and 
promoting the excretion of excess glucose in the urine [6, 8]. The 
sodium glucose cotransporter 2 (SGLT2), located in the proximal 
tubule of the nephron, is estimated to facilitate-90% of this 
reabsorption [9, 10]. It is a potent and selective competitive 
inhibitor of the SGLT2 protein. Sodium-glucose co-transporter 2 
(SGLT2) inhibitors offer an insulin-independent mechanism for 
improving blood glucose levels since they promote urinary glucose 
excretion (UGE) by inhibiting glucose reabsorption in the kidney. In 
addition to glucose control, SGLT2 inhibitors are associated with 
weight loss and blood pressure reductions and do not increase the 
risk of hypoglycemia [9]. 
 
Fig. 1: Metformin (MET) hydrochloride structure from pub chem 
 
 
Fig. 2: Empagliflozin (EMPA) structure from pubchem 
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Literature survey revealed that few analytical methods are reported 
for analysis of both the drugs alone as well as in combination using 
ultraviolet spectrophotometry [15, 22], high-pressure liquid 
chromatography (HPLC) [10, 12, 17-19, 23, 25, 26] and ultra-
pressure liquid chromatography [11]. To date, there have been no 
published reports about the simultaneous estimation of metformin 
HCl and empagliflozin by reverse phase ultra performance liquid 
chromatography (RP-UPLC) in bulk drug and in pharmaceutical 
dosage forms. Hence, an attempt has been made to develop a new 
method for simultaneous estimation and validation of MET and 
EMPA in tablet formulation in accordance with the International 
Conference on Harmonization (ICH) guidelines [26].  
MATERIALS AND METHODS 
Chemicals and reagents  
Metformin HCl and empagliflozin were procured gift sample from 
pharma train research solutions, Hyderabad. Tablets were procured 
from a local pharmacy containing 1000 mg (Metformin HCl) and 10 
mg (Empagliflozin). All solvents were of HPLC grade and all reagents 
were of analytical grade. Orthophosphoric acid was obtained from 
Merck (India), water and methanol for HPLC were obtained from 
lichrosolv (Merck), potassium dihydrogen orthophosphate was 
obtained from finer chemical Ltd and acetonitrile was obtained from 
molychem. All solvents and solutions were filtered through a 
membrane filter (Millipore Millex-HV filter units, 0.45 μm pore size; 
nylon) and degassed before use.  
Instrumentation  
The UPLC was carried out on the waters with empower 2695 separation 
module, auto Sampler and photodiode array (PDA) detector were used 
in the analysis. Ultraviolet-visible spectrophotometer (Labindia), 
Balance (Afcoset ER-200A) and pH meter (Adwa–AD 1020). 
Preparation of the metformin HCl and empagliflozin standard 
and sample solution 
Accurately weighed 10 tablets crushed in mortor and transferred 
equivalent to 1000 mg of metformin HCl and 10 mg empagliflozin 
sample into a 100 ml clean dry volumetric flask added about 70 ml 
of diluent and sonicated to dissolve it completely and made the 
volume up to the mark with the same solvent(Stock solution). 
Pipetted out 1.5 ml of metformin HCl and empagliflozin of the above 
stock solution into a 10 ml volumetric flask and diluted up to the 
mark with diluent. In a similar manner working standard solutions 
of metformin HCl and empagliflozin were prepared (150 µg/ml MET 
and 15 µg/ml of EMPA) [11, 13, 15, 16]. 
Chromatographic conditions 
Chromatographic conditions the UPLC system consisted of 2695 
separation module, autosampler and PDA detector. The wavelength 
of detection as set at 240 nm. Separation was carried out in dikma 
C18 (50×2.1 mm, 1.8 μ) and the retention time (RT) of metformin 
HCl and empagliflozinin was found to be 1.189 min and 1.712 min 
respectively shown in fig. 3, using mobile phase consisting 
phosphate buffer and methanol, pH 3.0 in the ratio of 30: 70 v/v at a 
flow rate of 1 ml/min with UV detection at 240 nm. The mobile 
phase was filtered through 0.45 µ filter under vacuum filtration [18, 
19, 21]. 
RESULTS AND DISCUSSION 
Method validation 
The developed method was validated as per ICH guidelines for its 
system suitability, linearity, accuracy, precision, and robustness, 




Fig. 3: Chromatogram of metformin HCl and empagliflozinin 
 
Accuracy 
Accuracy of the method was established by performing recovery 
studies of ICH guidelines. Spiked samples were prepared by pre-
analyzed sample solutions with the pure drug at three different 
concentration levels each in triplicate. The % mean recovery of 
metformin HCl (100.35-100.48%) and empagliflozin (99.80-
101.30 %) at each level were within the limits of 98% and 102% 
indicating that the method is more accurate shown in table 1, 
when compared with metformin HCl (100.64-100.89%) and 
empagliflozin (99.95-101.34) by hplc [27] method. The current 
research work indicates that retention time value is less than 2 
min which is a good recovery value of the existing method in 
comparison with HPLC method. 
Precision 
The Intraday precision was demonstrated by injecting standard 
solutions of metformin HCl and empagliflozin with 1500μg/ml and 
15μg/ml, respectively as per the test procedure and recording the 
chromatograms of six standard solutions. The % relative standard 
deviation (RSD) of metformin HCl and empagliflozin was found to be 
1 and 1.1 respectively shown in table 2. % RSD values were within 
the limits and the method was found to be precise. 
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Table 1: Accuracy data of metformin HCl and empagliflozin 
Metformin HCl 
% concentration (at specification Level), 
(n=3) 
Area Amount added (mg) Amount found (mg) % recovery % RSD 
50% 2403115 500 501.76 100.35 1.21 
100% 4830189 1000 1008.52 100.85 1.29 
150% 7218887 1500 1507.27 100.48 0.63 
Empagliflozin 
50% 102326 5.0 5.06 101.30 1.16 
100% 201600 10.0 9.98 99.80 1.29 
150% 304187 15.0 15.07 100.47 0.64 
 
Table 2: Precision data of metformin HCl and empagliflozin 
S. No. Metformin HCl Empagliflozin 
Area Area 
1 4669547 205555 
2 4633682 213714 
3 4711857 202403 
4 4586290 191233 
5 4690109 197507 
6 4674377 205189 
mean±SD,(n=6) 4660977.0±44751.8 192600.0±13583.0 
% RSD 1 1.1 
 
Intermediate precision 
The intermediate precision of the analytical method was determined 
by performing method precision on in three successive days by 
different analysts under same experimental condition by injecting 
six replicate standard preparations was determined and the mean % 
RSD of metformin HCl (1500μg/ml) and empagliflozin (15μg/ml) 
was found to be 0.9 and 0.8 respectively shown in table 3. % RSD 
values were within the limits and the method was found to be 
precise.
 
Table 3: Intermediate precision data of metformin HCl and empagliflozin 
S. No. Metformin HCl Empagliflozin 
Area Area 
1 4744291 195724 
2 4657794 204293 
3 4797415 204813 
4 4706370 204018 
5 4721262 191618 
6 4781858 201052 
mean±SD, (n=6) 4768164.9±86790.3 205252.9±16346.1 
%RSD 0.9 0.8 
 
Linearity 
The measurement of linearity was evaluated by analyzing different 
concentrations of the standard solution of metformin HCl and 
empagliflozin. For both the drugs, the Beer-lamberts law was obeyed 
in the concentration range 500-2500 μg/ml and 5-25 μg/ml for 
metformin HCl and empagliflozin respectively. The linearity of the 
proposed UPLC method was constructed by considering 
concentration (μg/ml) on X–axis and peak area on Y-axis. The 
regression coefficient was considered to be 0.98 over a 
concentration range of 500–2500 μg/ml (MET) and 0.99 over a 
concentration range of 5–25 μg/ml (EMPA). The representative 
linearity equation was found to be y = 2656x+53186 (MET) and y = 
12865x+27421 (EMPA) as showed in fig. 4 and 5 and the 
corresponding data were shown in table 4. For both the methods the 
% RSD was found to be within the acceptable theoretical limits of ≤ 
2%, which meet the method validation acceptance criteria and hence 
the method was said to be linear for both the drugs. 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD is calculated using the formula 3.3 times σ/s where “σ” is 
the standard deviation of the intercept obtained for calibration 
curve and “s” is the slope of the calibration curve. Similarly, LOQ is 
calculated using the formula 10 times σ/s. The calculated LOD and 
LOQ for MET and EMPA using the proposed method were found to 
be 0.2626 µg/ml, 0.795 µg/ml and 0.02615 µg/ml, 0.0792 µg/ml 
respectively. The results obtained were presented in table 5. 
 
Fig. 4: Linearity graph for metformin HCl 
 
 
Fig. 5: Linearity graph for Empagliflozin 
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Table 4: Linearity data of metformin HCl and empagliflozin 
S. No. Metformin HCl Empagliflozin 
Concentration(µg/ml) Area Concentration(µg/ml) Area 
1 500 1737625 5 93475 
2 1000 3100790 10 149362 
3 1500 4887985 15 230699 
4 2000 5851773 20 277360 
5 2500 7002614 25 351109 
Correlation coefficient  0.989  0.994 
 
Table 5: LOD and LOQ data of metformin HCl and empagliflozin 
Drug name Standard deviation(σ) Slope(s) Intercept LOD (µg/ml) LOQ (µg/ml) 
Metformin. HCl 2111167 2656 53186 0.2623 0.795 
Empagliflozin 101970.2 12865 27421 0.02615 0.0792 
 
Robustness 
Robustness were measured by making small, but deliberate changes in 
flow rate were varied at 0.9 ml/min to 1.1 ml/min and 10% organic 
content in mobile phase affected the method significantly. This 
deliberate change in the above parameters has no significant effect on 
the peak tailing, peak area and theoretical plates and finally the method 
was found to be robust and the results were shown in table 6. 
 
Table 6: Robustness data of metformin HCl and empagliflozin 
Parameter Metformin HCl Empagliflozin 
USP Plate count USP tailing USP Plate count USP tailing 
Less flow rate (0.8 ml/min) 2001.88 1.13 4005.09 1.15 
More flow rate (1.2 ml/min) 2796.68 1.09 3430.48 1.21 
Mobile phase(10% less) 2041.88 1.13 4025.09 1.15 
Mobile phase(10% more) 2796.68 1.09 3430.48 1.21 
 
Degradation studies 
ICH degradation was attempted to various stress conditions such as 
acid hydrolysis (0.1N HCl), base hydrolysis (0.1 N NaOH), oxidative 
hydrolysis (3% H2O2), thermal degradation (heated at 110 °C for 24 
h) and photolytic degradation (overall illumination of ≥210W h/m2 
at 25 °C for 7 d with UV radiation at 320-400 nm), to evaluate the 
ability of the proposed method to separate MET and EMPA from its 
degradation products [25]. It was observed that the drug degrades 
as shown by the decreased areas in the peaks when compared with 
peak areas of the same concentration of the non-degraded drug, 
with additional degradation peaks. Percent degradation was 
calculated by comparing the areas of the degraded peaks at each 
degradation condition with the corresponding areas of the peaks of 
both the drugs under non-degradation condition. Comparatively, 
more degradation was found with base, peroxide, photo, thermal for 
EMPA and with thermal for MET. There was no interference in any 
of the degradation products of the stress conditions tested in the 
current study. Thus, the developed method of analytical 
determination of MET and EMPA was established to be specific and 
stability-indicating. The results are shown in table 7 and fig. 
6,7,8,9,10 [20, 22]. 
 
Table 7: Degradation data of metformin HCl and empagliflozin 
Stress condition Metformin HCl Empagliflozin 
% assay % degraded % assay % degraded 
Standard 100 - 100 - 
Acid 97.6 2.40 94.03 5.97 
Base 94.56 5.44 91.3 8.70 
Peroxide 95.04 4.96 92.14 7.86 
Thermal 92.52 7.48 89.51 10.49 
Photo 95.15 4.85 91.04 8.96 
 
 
Fig. 6: Chromatogram of acid degradation 
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Fig. 7: Chromatogram of base degradation 
 
 
Fig. 8: Chromatogram of peroxide degradation 
 
 
Fig. 9: Chromatogram of photo degradation 
 
 
Fig. 10: Chromatogram of thermal degradation 
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CONCLUSION 
The newly developed UPLC method of metformin HCl and 
empagliflozin assay determination was found to provide faster 
retention time with a good resolution in the present study. A good 
linearity was obtained for both drugs (500-2500 µg/ml and 5-25 
µg/ml) with a correlation coefficient of 0.994 and 0.998 for 
metformin HCl and empagliflozin respectively. The results of 
precision, recovery and ruggedness were within limits. Hence the 
method was successfully applied for degradation studies. The UPLC 
method of simultaneous estimation of metformin HCl and 
empagliflozin was found to be a novel, simple, precise, accurate and 
effective method. There were no UPLC methods reported till now on 
the above-mentioned combination drugs. Hence the developed 
method is suitable for the routine analysis and percentage 
degradation of pharmaceutical preparations containing these drugs 
either individually or in combination. 
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